The Medical Imaging & Technology Alliance (MITA) today applauded Reps. Charles Boustany, Jr. MD (R-La.), John Barrow (D-Ga.), Jim Renacci (R-Ohio) and Richard E. Neal (D-Mass.) for their leadership in advocating for Medicare coverage of low-dose computed tomography (LDCT) for patients at high risk of lung cancer. 

Providers worldwide now have access to the American College of Radiology (ACR) Lung Imaging Reporting and Data System (Lung-RADS®) – a quality assurance tool to standardize lung cancer screening CT reporting and management recommendations, reduce confusion in lung cancer screening CT interpretations, and facilitate outcome monitoring.

The American Society for Radiation Oncology (ASTRO) is concerned by the Medicare Evidence Development and Coverage Advisory Committee’s (MEDCAC) April 30, 2014 recommendation to the Centers for Medicare and Medicaid Services (CMS) that adults at high risk for lung cancer should not receive Medicare coverage of annual, low-dose computed tomography (LDCT) screening.

At an April 30 meeting, Ella Kazerooni, MD, chair of the American College of Radiology (ACR) Committee on Lung Cancer Screening, will urge the 2014 Medicare Evidence Development and Coverage Advisory Committee (MedCAC), to recommend national Medicare coverage of low-dose computed tomography screening for patients at high risk for lung cancer.

The ability to measure a tumor’s oxygen levels could help guide treatment decisions, and now, for the first time, a method to reliably and noninvasively take such measurements could soon be available.

The BioZorb™ three-dimensional surgical marker improved the ability of radiation oncologists to target radiation treatment for breast cancer, according to a scientific presentation at the 2014 American Brachytherapy Society (ABS) Annual Meeting.

Researchers at the British Museum and Durham University in the U.K. have located a skeleton more than 3,000 years old that they say represents the oldest complete example of a human being with metastatic cancer.

Could a home colon cancer test boost screening rates, especially in underserved populations? That was the question asked by researchers at the Kaiser Permanente Center for Health Research.